On Demand
55 min
Share webinar
Alacris Theranostics' Comprehensive Molecular Tumor Analysis (CMTA) uses whole exome and transcriptome sequencing with MGI DNBSEQ technology. It's beneficial for guiding targeted therapies in complex or unknown tumors, enhancing personalized cancer treatment plans.
Dr. Marie-Laure Yaspo - Co-founder and Chief Scientific Officer @ Alacris Theranostics GmbH
Priyanka Kurapati - Field Application Scientist @ MGI-tech